300,000 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Bought by Tang Capital Management LLC

Tang Capital Management LLC acquired a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 300,000 shares of the company's stock, valued at approximately $3,309,000. Tang Capital Management LLC owned approximately 0.57% of Stoke Therapeutics at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Stoke Therapeutics during the fourth quarter worth approximately $63,000. Teacher Retirement System of Texas acquired a new stake in shares of Stoke Therapeutics during the fourth quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Stoke Therapeutics during the fourth quarter worth approximately $124,000. Tower Research Capital LLC TRC increased its holdings in shares of Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after buying an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in shares of Stoke Therapeutics during the fourth quarter worth approximately $133,000.

Stoke Therapeutics Stock Down 5.7%

STOK stock traded down $0.57 during midday trading on Wednesday, reaching $9.48. The company's stock had a trading volume of 512,054 shares, compared to its average volume of 712,952. The business's 50-day simple moving average is $8.22 and its 200-day simple moving average is $9.92. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $17.58. The stock has a market cap of $517.58 million, a PE ratio of -4.51 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, equities analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

STOK has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Chardan Capital reissued a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $23.20.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is owned by insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.